Immune checkpoint inhibitors targeting CTLA-4 and PD-1, as well as neutralizing antibodies against chemokines or the corresponding receptors on Tregs, are showing promise in many cancers such as NSCLC (98, 131). The gene discussed is PDCD1; the disease is cancer.